Table of Contents Author Guidelines Submit a Manuscript
International Journal of Microbiology
Volume 2016 (2016), Article ID 2543156, 7 pages
Research Article

Comparison of Procleix Ultrio Elite and Procleix Ultrio NAT Assays for Screening of Transfusion Transmitted Infections among Blood Donors in India

1Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
2Department of Transfusion Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareilly Road, Lucknow 226014, India
3Hemogenomics Pvt. Ltd., New Delhi 110044, India

Received 26 September 2015; Revised 18 December 2015; Accepted 29 December 2015

Academic Editor: Rino Ragno

Copyright © 2016 Rahul Chaurasia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Introduction of nucleic acid testing (NAT) has helped in decreasing window period donations, resulting in increased safety of blood supplies. NAT combines the advantages of direct and highly sequence-specific detection of viral genomes. We analysed the performance of newer Procleix Ultrio Elite (PUE) and Procleix Ultrio assay (PUA) for the screening of the viral markers in our donor population. Material and Methods. 10,015 donor samples were screened by routine immunoassays and both versions of NAT. NAT yields detected were subjected to viral load estimation and to other serological markers. Results. A total of 21 NAT yields were detected; three were positive by both NAT systems, whereas 18 samples were reactive by PUE only. NAT yields include 18 HBV and 3 HCV yields, of which 17 HBV yields were occult infections and 1 was window period (WP) infection. All 3 HCV yields were WP infections. No HIV-1/HIV-2 yield was found. Conclusion. Efficient target capture chemistry in the new TMA assay version significantly improved sensitivity. NAT is superior to serological immunoassays for screening of the viral markers; and the efficient target capture system in the newer TMA assay, namely, the PUE system, has significantly improved sensitivity over the earlier versions.